Shares of ARK Genomic Revolution ETF (BATS:ARKG – Get Free Report) reached a new 52-week high during trading on Monday . The stock traded as high as $43.98 and last traded at $43.86, with a volume of 1805851 shares changing hands. The stock had previously closed at $42.91.
ARK Genomic Revolution ETF Stock Down 1.9%
The company has a fifty day moving average price of $34.11 and a 200 day moving average price of $30.95.
Institutional Trading of ARK Genomic Revolution ETF
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its holdings in ARK Genomic Revolution ETF by 207.8% in the fourth quarter. SG Americas Securities LLC now owns 102,521 shares of the company’s stock worth $2,970,000 after purchasing an additional 69,215 shares in the last quarter. Canal Insurance CO bought a new stake in shares of ARK Genomic Revolution ETF during the 4th quarter valued at $3,476,000. Kingsview Wealth Management LLC purchased a new stake in shares of ARK Genomic Revolution ETF in the 4th quarter worth about $5,975,000. Wealth Enhancement Advisory Services LLC grew its position in shares of ARK Genomic Revolution ETF by 136.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 41,056 shares of the company’s stock worth $1,293,000 after buying an additional 23,662 shares during the period. Finally, Moran Wealth Management LLC increased its stake in shares of ARK Genomic Revolution ETF by 79.6% in the 1st quarter. Moran Wealth Management LLC now owns 49,204 shares of the company’s stock worth $1,300,000 after acquiring an additional 21,811 shares in the last quarter.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Stories
- Five stocks we like better than ARK Genomic Revolution ETF
- These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential
- Vertex’s Crinetics Deal Balances Growth with Integration Risk
- Stacking Chips: The Hidden Supply Shock Fueling Intel
- Drone Stocks Are Down, But Defense Backlogs Tell a Different Story
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
